The National Blood Authority (NBA) manages the appropriate use of Ig in Australia in accordance with the approved indications set out in the criteria. This is applicable for both intravenous (IV) and subcutaneous (SC) immunoglobulins.
The National Blood Authority has introduced the supply and governance structure to address the continued growth in demand for IVIg aimed at ensuring equity and sustainability of this resource.
IVIg changes to supply and governance
Blood Matters have produced resources for the changes to the supply of intravenous immunoglobulin.
Reviewed 21 September 2020